These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 22310609

  • 1. Early steroid withdrawal in adult kidney transplantation at a single center.
    Iwamoto H, Hama K, Konno O, Yokoyama T, Kihara Y, Jojima Y, Nakamura Y, Takeuchi H, Shimazu M.
    Transplant Proc; 2012 Jan; 44(1):179-81. PubMed ID: 22310609
    [Abstract] [Full Text] [Related]

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 3. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, Klepetko W.
    J Thorac Cardiovasc Surg; 2003 Apr 20; 125(4):891-900. PubMed ID: 12698153
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec 20; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM, Marcus RJ, Ko TY, Nashar K, Thai NL, Sureshkumar KK.
    Exp Clin Transplant; 2016 Jun 20; 14(3):287-93. PubMed ID: 27221720
    [Abstract] [Full Text] [Related]

  • 10. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.
    Transplant Proc; 2012 Dec 20; 44(10):2961-5. PubMed ID: 23195006
    [Abstract] [Full Text] [Related]

  • 11. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H, Takahara S, Amada N, Tomikawa S, Chikaraishi T, Takahashi K, Uchida K, Akiyama T, Tanabe K, Toma H, Study Group for the Antimetabolite Comparison of Trial (AMCT).
    Exp Clin Transplant; 2016 Oct 20; 14(5):518-525. PubMed ID: 27733107
    [Abstract] [Full Text] [Related]

  • 12. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 20; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 13. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Sánchez-Fructuoso AI, Marques M, Conesa J, Ridao N, Rodríguez A, Blanco J, Barrientos A.
    Transpl Int; 2005 May 20; 18(5):596-603. PubMed ID: 15819810
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 20; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA.
    Exp Clin Transplant; 2011 Oct 20; 9(5):295-301. PubMed ID: 21967254
    [Abstract] [Full Text] [Related]

  • 16. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan 20; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 17. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
    Andrade-Sierra J, Rojas-Campos E, Cardona-Muñoz E, Evangelista-Carrillo LA, Puentes-Camacho A, Lugo-López O, Gómez B, Valdespino C, Cerrillos I, Medina-Pérez M, Jalomo B, Nieves JJ, Sandoval M, Ramos-Solano F, Monteón-Ramos F, Cueto-Manzano AM.
    Nefrologia; 2014 Jan 20; 34(2):216-22. PubMed ID: 24658197
    [Abstract] [Full Text] [Related]

  • 18. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun 20; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 19. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S, Sato S, Sekijima M, Iwado K, Urashima Y, Kudo S, Kai K, Koyama I, Tojinbara T, Nakajima I, Fuchinoue S.
    Transplant Proc; 2005 Mar 20; 37(2):791-4. PubMed ID: 15848533
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.